| 摘要 |
<p>The present invention is concerned with novel hydroxamic acid derivatives of formula (I) and their use in medical therapy, particularly in the prophylaxis or treatment of clinical conditions for which an inhibitor of the lipoxygenase or cyclooxygenase mediated arachidonic acid metabolic pathway is indicated. The invention also relates to pharmaceutical formulations and processes for the preparation of compounds according to the invention. In formula (I) Y is -C(Q)=C(Q')-((E)- or (Z)-) wherein Q and Q' are independently selected from hydrogen, C1-4 alkyl and halo, or Y is -C C-; R is C1-4 alkyl optionally substituted by fluoro; D is C1-4 alkyl, phenyl or -NR1R2 (wherein R?1 and R2¿ are independently selected from hydrogen, C¿1-4? alkyl, and phenyl); and ring A and ring B are each optionally substituted by a group or groups independently selected from halo, cyano, nitro, hydroxy, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, -C(O)OR?3¿, -C(O)R3, -C(O)NR?3R4, -NR3R4¿, -NHCOR3, -NHCO¿2R?3, -NHC(O)NR3R4, -NHSO¿2?R?3, -SO¿2NR3R4 (wherein R?3 and R4¿ are independently selected from hydrogen, C¿1-4? alkyl and phenyl), and -S(O)nR?5¿ (wherein n is an integer of from 0 to 2 and R5 is C¿1-4? alkyl, C6-10 aryl (for example, phenyl or naphthyl), or C8-12 aralkyl).</p> |
